Scancell Share Discussion Threads

[inanaco] 18/11/2024 11:12

what ever 2 tyke ... fact is this ... its an accumulation over the years

last year i was told £150,000 was a Huge holding and i should be careful

this years it £250,000 and i should be careful ....

1 days figures are not a basis to invest ... with Calculus still selling down we have to wait them out ....

and those patients are getting benefit if that continues ORR goes up as well as PFS and Complete response ....

this is the basis of approval to access a $1.5b market that is my goal

if the share price dips i buy more but this is my average of buys this year 0.134671625 on over £10,000

do i care what you have not bought ..... moby

not in the slightest ...

[2tyke] 18/11/2024 10:57

In the case of this stock inane it's no-buy.
SCLP showing a massive reversal candle today....on huge volume.
Not good.
Combine that with EW analysis and your past yearly buys look like they'll be in trouble shortly !

[inanaco] 18/11/2024 10:51

Moby with no money or short for no-buy

[inanaco] 18/11/2024 10:42

its not what Bitcoin has done it is what you have done ....

[2tyke] 18/11/2024 10:39

Yet again the sheep braying for 'news' and 'data' got their wish....and yet again the share price didn't go with their expectations.
Nonetheless, it'll all be different next time.. lol.
It simply all about intellectual honesty.
You have it....or you don't !

[2tyke] 18/11/2024 10:33

Make money on sclp ? Lol
£10 in Bitcoin 15 years ago delivered £6 million.
Little inane and his big ideas.
I wish Elon would fly the idiot away somewhere !

[inanaco] 18/11/2024 10:23

pretty obvious Calculus ... !! its not that we cant get a higher share price ... the demand is being met by supply

it will end ....

when

[gazza] 18/11/2024 10:22

Trinity Delta view: Data from the SCOPE study are reassuring and pave the way for the planned randomised adaptive Phase II/III trial. Assuming continuing positive results at week 25 for both Cohorts 1 and 3, investor attention will understandably centre on the funding of this potentially pivotal study. Our forecast cash runway extends to Q325, beyond these SCIB1/iSCIB1+ milestones and Modi-1 data in H125; however, our cash assumptions do not include any potential licensing deals for the GlyMab and/or AvidiMab antibody platforms. We note that the seven-month evaluation deal with an unnamed partner could result in option exercise in Q125, which could trigger a similar upfront payment and licence deal to that struck with Genmab in October 2022. Our current risk adjusted NPV valuation for Scancell is £311m, equivalent to 33p per share.

[sci102] 18/11/2024 10:22

Hint:

"Sci102 25 Oct '24 - 15:57 - 541 of 546 Edit
0 0 0
What's with the "(target lesions)" qualifier on the data lately, while at the same time no mention of recist 1.1 protocol?

Per recist, though only target lesions are plotted, new lesions are indicated with an asterisk, like they have shown previously with modi 1 monotherapy.

PS no way 1st patient dosed for phase 2/3 in 2025. Q1 2026 at best as it stands now"

This and more later

[inanaco] 18/11/2024 10:15

so there you go .... you can make money in Scancell

[inanaco] 18/11/2024 10:14

just checked 14.44

2250 at 13.45
1000 at 13.41
1000 at 13.6
1000 at 13.65
1000 at 13.25
1000 at 14.92
500 at 14.5
800 at 15.08
1000 at 10.7

so correction highest paid 15.08 since april 3rd

[sci102] 18/11/2024 10:13

I will deliver my final report after market closes. We can discuss then if you want but only on my thread for obvious reasons.

How was the 13 or 19 week data banked if it's 25 weeks that matters? Come on...

[bermudashorts] 18/11/2024 10:09

Sci102

Look what I will say is that I didn't dismiss your points out of hand, your comments prompted me to double check with LD and so I'm grateful to you for that. She confirmed that my understanding was correct - I don't know what else I can add. It matters not now because these patients have reached 25 weeks and I'd much rather be discussing the results announced today.

[inanaco] 18/11/2024 10:06

highest paid was £600 at 14.6

[inanaco] 18/11/2024 10:05

depends ... i picked up the majority this year since April around 12/13 even on the dip its still all OK in my book ...

as the data is reinforcing no Risk ...

[gazza] 18/11/2024 10:01

"Lets not forget Burble didn't want to buy anymore ... better shares else where LOL"Looks like he is rightl

[nigelpm] 18/11/2024 09:59

Surprised at lack of movement. To me that RNS derisks quite a bit. We're still left with potential funding challenges but even so. I guess the insiders who were buying on Thursday and Friday have sold on news.

[sci102] 18/11/2024 09:57

Well Bermuda, I hope at least you understand the point of view of someone that does not need to rely on what management says via email/chat/interviews/even RNS to make their assessment.

[markingtime] 18/11/2024 09:53

There is only one clown here, Sci102. That's you......

[bermudashorts] 18/11/2024 09:37

Trinity Delta's update

[chilltime] 18/11/2024 09:34

Marcus

He’s off his trolley la la land nut job just ignore him.

He’ll be back off to Hvivo soon🙌

[bermudashorts] 18/11/2024 09:29

Sci102

Yes (well almost)